The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Barclays raised its price target on Relay Therapeutics to $27 from $21 while maintaining an ‘Overweight’ rating, implying a potential upside of 124% from RLAY’s closing price on Tuesday. ・The firm ...

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with ...

Relay Therapeutics clinical trial results shows targeted therapy drug shrank tumors in patients rare blood vessel cancers The ...

Relay Therapeutics has two cancer drugs in early clinical development and one more close behind—all of them discovered and developed with proprietary computational technology that finds ways to drug ...